Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Stage IV Colorectal Cancer AJCC v8 Clinical Trial

Official title:

A Phase II Study of Preoperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03844750
• Other study ID #: 187015
• Secondary ID: NCI-2018-03165
• Status: Recruiting
• Phase: Phase 2
• Start date: July 22, 2019
• Est. completion date: June 30, 2024

Study information

• Verified date: October 2023
• Source: University of California, San Francisco
• Contact: UCSF HDFCCC Cancer Immunotherapy Program (CIP)
• Phone: (877) 827-3222
• Email: HDFCCC.CIP[@]ucsf.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trials studies how well pembrolizumab and vactosertib work after standard of care chemotherapy in patients with colorectal cancer that has spread to the liver that can be removed by surgery (resectable hepatic metastases). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vactosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and vactosertib after standard of care chemotherapy, but before liver metastases surgery, may help shrink the cancer prior to surgery. This study also investigates pembrolizumab and vactosertib after liver metastases surgery, decrease the risk of the cancer recurring (coming back).

Description:

PRIMARY OBJECTIVE:

I. To characterize the change in the populations of tumor infiltrating lymphocytes (TILs) induced by neoadjuvant pembrolizumab plus vactosertib in patients with metastatic colorectal cancer (mCRC).

SECONDARY OBJECTIVES:

I. To establish the safety/toxicity profile of pembrolizumab-based treatment in the perioperative setting for patients with colorectal cancer (CRC) with resectable hepatic metastases.

II. To explore the efficacy of pembrolizumab plus vactosertib in patients with CRC with resectable hepatic metastases.

EXPLORATORY OBJECTIVES:

I. To determine the impact of pembrolizumab-based treatment on PD-L1 expression in tumor cells and tumor-infiltrating immune cells (TIICs), in patients with mCRC.

II. To determine the change in T cell repertoire within the tumor and blood induced by neoadjuvant pembrolizumab-based treatment in patients with mCRC.

III. To explore molecular profiles to identify potentially predictive biomarkers for patients with metastatic CRC treated with immunotherapy (including but not limited to microsatellite instability (MSI) testing).

IV. To correlate change in TIICs, PDL-1 expression, and T cell repertoires as well as molecular profiles with response/resistance and toxicity.

V. To identify immune response messenger ribonucleic acid (mRNA) expression analysis to derive signatures associated with tumor response.

VI. To identify genomic mutations and gene copy aberrations associated with response and resistance to therapy.

VII. To correlate changes in microbiome composition and diversity with diet and lifestyle factors.

OUTLINE:

Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and vactosertib orally (PO) once a day (QD) for the first cycle 5 days a week and twice daily (BID) 5 days a week for cycle 2 and greater followed by a 2-day resting period for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgical removal of liver metastases approximately 2 weeks (minimum 1 week) after last dose of vactosertib.

OPTIONAL ADJUVANT TREATMENT: After surgery, eligible patients may also receive pembrolizumab and vactosertib every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients who do not undergo optional adjuvant treatment are followed up at 14 days and then every 90 days for up to 1 year. Patients who undergo optional adjuvant treatment are followed up at 30 days and then every 90 days for up to 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 19
• Est. completion date: June 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has histologically or cytologically confirmed CRC with liver metastases. In addition to liver metastases, extrahepatic metastases (e.g. pulmonary metastases) may be permitted if all other eligibility criteria are met. Patients are permitted to have primary tumor in situ (Neoadjuvant Arm only).

2. Has received previous oxaliplatin-based chemotherapy.

a. FOLFOX or capecitabine combined with oxaliplatin (CapeOx) does not need to be a direct lead-in to this study.

b. If chemotherapy is a direct lead-in to this study, concurrent mAb therapy (bevacizumab, cetuximab, or panitumumab) is acceptable, however the antibody must be omitted from the final cycle of chemotherapy prior to pembrolizumab.

3. Is an appropriate candidate to undergo liver biopsy and resection (+/-ablation) of liver metastases according to the interpretation of the Multidisciplinary Gastrointestinal (GI) Tumor Board (Neoadjuvant Arm Only).

4. Is willing and able to provide written informed consent/assent for the trial. The patient may also provide consent for Future Biomedical Research. However, the patient may participate in the main trial without participating in Future Biomedical Research.

5. Is >=18 years of age on day of signing informed consent.

6. Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions (Neoadjuvant Arm Only).

7. Is willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained after last dose of standard of care lead-in chemotherapy [if applicable] and within 28 days prior to first dose of pembrolizumab (Neoadjuvant Arm Only).

8. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

9. Has adequate organ function as defined below. All screening labs should be performed within 10 days of treatment initiation.

• Absolute neutrophil count (ANC) >= 1,500/microliter (uL) (within 10 days of treatment initiation).

• Platelets >= 100,000/uL (within 10 days of treatment initiation).

• Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment).

• Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate (GFR) can also be used in place of creatinine or creatinine clearance (CrCl)) >= 60 mL/min for patient with creatinine levels > 1.5 x institutional ULN (within 10 days of treatment initiation).

• Creatinine clearance should be calculated per institutional standard.

• Serum total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for patients with total bilirubin levels > 1.5 ULN (within 10 days of treatment initiation).

• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase (SGPT)) =< 2.5 x ULN (within 10 days of treatment initiation).

• Albumin >= 2.5 mg/dL (within 10 days of treatment initiation).

• International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (within 10 days of treatment initiation).

• Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 10 days of treatment initiation).

10. Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication (day 1). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

11. Female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication.

12. Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.

*Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.

13. Have locally confirmed microsatellite stable (MSS) or Mismatch repair proficient (pMMR) Colorectal cancer (CRC). MSS is defined as 0-1 allelic shifts among 3-5 tumor microsatellite loci using a Polymerase chain reaction (PCR)-based assay. pMMR is defined as presence of protein expression of 4 DNA mismatch repair (MMR) enzymes (MLH1, MSH2, MSH6 and PMS2) by immunohistochemistry.

Exclusion Criteria:

1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

• Note: Patients who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks since the last dose of the previous investigational agent or device use.

2. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

3. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority.

4. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.

5. Has active hepatitis B (defined as hepatitis B surface antigen (HBsAg) reactive) or active hepatitis C virus (HCV) (defined as HCV RNA [qualitative] is detected) infection.

6. Has received prior anti-cancer monoclonal antibody (mAb), systemic anticancer therapy other than FOLFOX (including investigational agents), targeted small molecule therapy, or radiation therapy within 14 days prior to the first dose of study treatment (day 1).

• Note: Patients must have recovered from all adverse events (AEs) due to a previous therapies to =< grade 1 or baseline. Patients with grade 2 neuropathy or alopecia are eligible. If a patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.

7. Has received FOLFOX less than 7 days prior to the first dose of study treatment (day 1). Has not recovered (i.e., =< grade 1 or at baseline) from AEs due to FOLFOX chemotherapy.

• Note: Patients with =< grade 2 neuropathy or alopecia are exceptions to this criterion and may qualify for the study.

8. Has not recovered adequately from toxicity or complications of a surgery or other procedure, per the assessment of the treating investigator.

9. Has received liver-directed therapy such as radiotherapy or yttrium-90 in the past year involving the lesion to be biopsied. (Neoadjuvant Arm only)

10. Has a known additional malignancy that is progressing or has required active treatment within 5 years prior.

• Note: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.

11. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable (i.e., without evidence of progression by imaging for at least 4 weeks by repeat imaging [repeat imaging should be performed during the study screening]), clinically stable, and without requirement of steroid treatment for at least 14 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.

12. Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.

13. Has an active infection requiring systemic therapy.

14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator. Anticoagulation that cannot be safely held to perform the liver biopsy is an example of a contraindication to participation.

15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Has received any prior immunotherapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137). (Neoadjuvant Arm Only).

17. Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or to any of pembrolizumab's excipients.

18. Has received a live or live-attenuated vaccine within 30 days prior to first dose of the trial drug. Administration of killed vaccines are allowed.

19. Has inferior vena cava/cardiac involvement based on imaging. 20. Has had encephalopathy in the last 6 months. Those patients on rifaximin or lactulose to control their encephalopathy are not allowed.

21. Has had a solid organ or hematologic transplant. 22. Has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions (including therapeutic thora- or paracentesis) is eligible.

23. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III/IV), uncontrolled hypertension (>=150/90mmHg), unstable angina pectoris or myocardial infarction (= 6 months prior to screening), uncontrolled cardiac arrhythmia, clinically significant cardiac valvulopathy requiting treatment, active interstitial lung disease, or serious chronic gastrointestinal conditions associated with diarrhea.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Malignant Neoplasm in the Liver
• Neoplasm Metastasis
• Neoplasms
• Stage IV Colorectal Cancer AJCC v8
• Stage IVA Colorectal Cancer AJCC v8
• Stage IVB Colorectal Cancer AJCC v8
• Stage IVC Colorectal Cancer AJCC v8

Intervention

Procedure:
• Hepatectomy
Undergo liver resection.

Biological:
• Pembrolizumab
Given IV

Drug:
• Vactosertib
Given orally once a day (QD) for cycle 1, and twice a day (BID) for cycle 2 and beyond

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (3)

Lead Sponsor	Collaborator
Chloe Atreya, MD, PhD	MedPacto, Inc., Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with a >= 2-fold increase in the tumor-infiltrating cells per unit area (5 high power fields) in post- versus pre pembrolizumab treatment tumor specimens.	Tumor-infiltrating immune cells (TIICs) will be analyzed by immunohistochemistry (IHC) in pre- and post-pembrolizumab treatment tumor specimens. The proportion of patients with a >= 2-fold increase (from pre- to post-treatment) in the number of TIICs per unit area (5 high power fields) will be calculated.	Up to 2 years
Secondary	Proportion of participants with treatment-related, adverse events	Adverse events (AEs) will be analyzed including but not limited to all AEs, serious (S)AEs, and fatal AEs using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5 for classification. Due to the potential for late toxicities from pembrolizumab, patients will be followed for 1 year after their last dose of pembrolizumab.	Up to 2 years
Secondary	Proportion of participants with events of clinical interest (ECIs)	Specific immune-related AEs (irAEs) will be collected and designated as immune-related events of clinical interest (ECIs). The study will use descriptive statistics to report on the safety/toxicity. Due to the potential for late toxicities from pembrolizumab, patients will be followed for 1 year after their last dose of pembrolizumab	Up to 2 years
Secondary	Proportion of participants with perioperative complications	The proportion of participants with reported perioperative complications related to study treatment will be reported.	Up to 1 month
Secondary	Proportion of participants with an R0 resection	Participants who undergo surgical resection of liver metastases will be evaluable and the proportion of participants requiring an R0 resection will be reported	Up to 1 month
Secondary	Pathologic response rate	Participants who undergo surgical resection of liver metastases will be evaluable and the proportion of participants with a pathological tumor response will be reported	Up to 1 year
Secondary	Objective response rate (ORR)	Participants with a complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be reported.	Up to 1 year
Secondary	Median Relapse-free survival (RFS) per RECIST 1.1	The time from objective response to progression or death will be used to determine relapse-free survival.	Up to 2 years